- Changing the Therapeutic Landscape in Non-small Cell Lung Cancers: the Evolution of Comprehensive Molecular Profiling Improves Access to Therapy. Current oncology reports. 2017 Academic Article GET IT
- The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers. Cancers. 2017 Academic Article GET IT
Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.
Annals of oncology : official journal of the European Society for Medical Oncology.
Times cited: 2
- Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase. Lung cancer (Amsterdam, Netherlands). 2014 Academic Article GET IT
Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial.
The Lancet. Oncology.
Times cited: 47